化学
化学合成
组合化学
生物活性
药理学
立体化学
生物化学
体外
医学
作者
Chunlei Tang,Jie Wang,Dong Wang,Huabing Wang,Shuang Cui,T. D. Xiao,Weizheng Fan,Yan Zhang
标识
DOI:10.1016/j.bmcl.2024.129648
摘要
In the treatment of non-small cell lung cancer (NSCLC), acquired drug resistance is a major factor that affects the efficacy of third-generation epidermal growth factor receptor (EGFR) inhibitors like Osimertinib. To overcome the L858R/T790M/C797S mutation, taking the Brigatinib as the positive control, two classes of 20 target compounds were designed and synthesized with 2-phenylaminopyrimidine as the core structure on the basis of summarizing the structure–activity relationship (SAR), following the basic principles of drug design. Representative compound I-10 potently inhibited EGFRL858R/T790M/C797S with an IC50 value of 33.26 nM and suppressed Ba/F3-EGFRL858R/T790M/C797S cells with an IC50 value of 106.4 nM, which is 5-fold more potent than Brigatinib. Besides, the compound exhibited an inhibition rate of less than 50 % against wild-type cell (NCI-H838), which reflected its toxicity or selectivity. Furthermore, this work serves as a foundation for future studies on EGFR inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI